The Company has secured an exclusive worldwide licence to commercialise biomarkers that can test for oesophageal adenocarcinoma, the most common form of oesophageal cancer.
The licence agreement comes after Proteomics International and QIMR Berghofer validated the biomarkers in a joint study of more than 300 patients earlier this year [ASX: 4 February]. The patent family, titled “Glycoprotein Biomarkers for Esophageal Adenocarcinoma and Barrett’s Esophagus and Uses Thereof”, covers patents already granted in Australia, China, Hong Kong, and Europe (France, Germany, Spain, Turkey, United Kingdom) (with expiry November 2035), with further patents pending in the United States and Canada.
